Agenda
*All times are in CEST
Jul
Fri 07
11:00am-12:30pm
Hematopathology virtual webinar
Sanam Loghavi, Mina Xu, Robert Hasserjian
- Diagnostic assessment and differential diagnosis of fibrotic and hypoplastic bone marrow specimens
Robert Hasserjian
Panel discussion
- The phenotypic spectrum of TP53 mutations in myeloid neoplasms
Sanam Loghavi
Panel discussion
- Tackling clonal hematopoiesis and germline predispositions to myeloid neoplasms
Mina Xu
Panel Discussion
- Diagnostic assessment, clinical consequences and differential diagnostic considerations of hypoplastic bone marrow
Anne Sophie Kubasch
Panel Discussion
1:00pm-2:30pm
Meeting Registration
2:30pm-2:40pm
Introduction & meeting objectives and keynote talks – Amer Zeidan
2:40pm-3:20pm
Session I: CHIP/CCUS – Michael Savona and Uma Borate
- The SEARCH CONSORTIUM: Looking for Answers in CHIP And CCUS; Zhuoer Xie
- Clonal Hematopiesis and transplantation outcomes; Coleman Lindsley
- Should CCUS be considered as lower risk MDS?; Uma Borate
- Putting it all together; Michael Savona
Panel discussion
3:50pm-4:10pm
Break
4:10pm-4:30pm
Keynote talk:
Leveraging the icMDS combined database to answer timely and important questions
on classification and risk stratification in MDS: Matteo Della Porta
4:30pm-5:0pm
Session II: CMML – Michael Savona and Valeria Santini
- RASopathies; Key Features of Ras-Family Mutated CMML, and Treatment Options; Mrinal Patnaik
- Approaches from the MDS/MPN IWG: ABNL MARRO, and beyond; Daniel Wiseman
- Elucidating the role of HMAs in CMML-A standard of care or not? Lisa Pleyer
- The Special Case of MDS/MPN-RS-T; Valeria Santini
Panel discussion
5:20pm-5:45pm
Lifetime Awards
5:45pm-5:50pm
Wrap-up Day 1
Jul
Sat 08
8:00am-9:10am
Session III: Epigenetics and Splicing
Chairs: Valeria Santini and Elizabeth Griffiths
- Oral hypomethylating agents in MDS-what is next?; Elizabeth Griffiths
- Updates in therapeutic combinations of epigenetic agents in MDS/AML; Aristoteles Giagounidis
- Pathophysiology and targeting of splicing factor mutant MDS and CMML; Jacqueline Boultwood
- Overview of the NIH Program for MDS; Alain Mina
Panel discussion
9:20am-10:20am
Session IV: Inflammation and Immune interventions
Chairs: Andrew Wei and Rena Buckstein
- Targeting inflammation & dysregulated innate immunity in MDS; Shahram Kordasti
- Updates in Vexas Syndrome; Carmelo Gurnari
- IRAK inhibitors in MDS and AML; Uwe Platzbecker
- How can we optimize transplant outcomes for MDS?; Charles Craddock
- What we have learn from AML immune contexture that can be relevant to MDS?; Leonido Luznik
Panel discussion
10:40am-1:10pm
Session V: Classification and risk stratification Updates
Chairs: Rena Buckstein and Maria Teresa Voso
- Roadmap for harmonization of classifications; Somedeb Ball
- Molecular data integration in prognostic tools; Elli Papaemmanuil
- Prognosis assessment in resource-limited countries; Maria Teresa Voso
- Predicting relapse risk in MDS post-transplant: Ready for primetime? Christopher Hourigan
- The Role of Classification versus Prognostication in MDS Patients; Robert Hasserjian
Panel discussion
2:10pm-3:00pm
Session VI: Response assessment & regulatory considerations
Chairs: Amer Zeidan/Kelly Norsworthy
- Proceedings from FDA/NCI workshop on drug development in MDS; Kelly Norsworthy
- How can we measure disease modification in LR-MDS; Rami Komrokji
- Are molecular responses ready for prime time use in MDS? Katharina Götze
- IWG response criteria evolution for higher risk MDS; Amer Zeidan
Panel discussion
3:00pm-3:20pm
Break
3:30pm-4:20pm
Session VII: TP53 aberrations and Secondary AML
Chairs: Valeria Santini & Andrew Wei
- How to use TP53 status for clinical decisions in MDS?; Coleman Lindsley
- Therapies for secondary AML; Thomas Cluzeau
- Targeting the CD47-SIRPa axis in MDS/AML; David Sallman
- TP53 focused initiative in MDS MyeloMatch; Maximilian Stahl
- Putting it together: current and future perspectives in TP53 mutated AML; Andrew Wei
Panel discussion
4:20pm-5:40pm
Session VIII: Advances in LR-MDS therapies
Chairs: Uwe Platzbecker & Olatoyosi Odenike
- Telomerase inhibition; Uwe Platzbecker
- TGF pathway modulation; Lionel Ades
- Should lenalidomide become SOC in del5q LR-MDS before needing transfusions? María-Díez Campelo
- myeloMATCH efforts to move clinical trial development ahead in MDS; Olatoyosi Odenike
- Putting it together-how do I manage LR-MDS in 2023; Valeria Santini
Panel discussion
Jul
Sun 09
9:00am-10:10am
Session IX: Updates in HR-MDS therapies
Chairs: Andrew Wei and Amer Zeidan
- IDH inhibitors- mono or combination therapy in MDS?; Marie Sebert
- RARA agonists- Updates in use of RARA agonists in MDS?; Amy DeZern
- Updates on TIM3 targeting in MDS and AML?; Amer Zeidan
- Putting all together; New directions in management of HR-MDS Andrew Wei
Panel discussion
10:00am-11:20am
Session X: Big data and quality of life measures
Chairs: Rena Buckstein and Mikkael Sekeres
- Should we include frailty and geriatric assessment in prognostic tools; Rena Buckstein
- The HARMONY Alliance: A Big Data platform for patients with hematologic malignancies; Guillermo Sanz
- Artificial Intelligence for MDS prognostication; Adrián Mosquera Orgueira
- QOL in MDS: what are its predictors and what does it predict?; Fabio Efficace
- How should we integrate quality of life as an endpoint in trials; Mikkael Sekeres
Panel discussion
11:20am-11:40am
break
11:40am-12:25pm
Open forum discussion and future plans for iwMDS
12:25pm-12:30pm
Conclusions and closing remarks-Amer Zeidan